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Surgical treatment of secondary (SHPT) and tertiary hyperparathyroidism (THPT) may involve various surgical approaches. The
aim of this paper was to evaluate presternal intramuscular autotransplantation of parathyroid tissue as a surgical option in SHPT
and THPT treatment. 66 patients with renal chronic disease underwent surgery from April 2000 to April 2005 at Universidade
Federal S˜ ao Paulo, Brazil. There were 38 SHPT patients (24 women/14 men), mean age of 39.yrs (range: 14–58), and 28 THPT
patients (14 women/14 men), mean age of 43.4 yrs (range: 24–62). Postoperative average followup was 42.9 months (range: 12–
96). Postoperative intact PTH increased throughout followup from 73.5 pg/mL to 133pg/mL on average from 1st to the 5th year,
respectively, in SHPT and from 54.9pg/mL to 94.7pg/mL on average from 1st to 5th year, respectively, in THPT group. Deﬁnitive
hypoparathyroidism was observed in 4 (6.06%) patients and graft-dependent recurrence in 6 (9.09%). Presternal intramuscular
autotransplantation of parathyroid tissue is a feasible and safe surgical option in SHPT and THPT treatment.
1.Introduction
Secondary hyperparathyroidism is a frequent and potentially
severe complication in patients with renal chronic disease,
evolving metabolic bone disease, severe atherosclerosis, and
undesirable cardiovascular events. Despite recent advances
in medical therapy, surgical approach is necessary in a
considerable number of uremic patients [1]. The best
surgical approach for renal hyperparathyroidism is yet to be
deﬁned. Controversy remains thus raising relevant questions
regarding treatment election, once neither high postsurgical
recurrence rates nor risks of deﬁnitive hypoparathyroidism
are intended.
T h ea i mo ft h i sp a p e rw a st oe v a l u a t eh y p e r p a r a t h y -
roidism recurrence rates and prevalence of deﬁnitive hypo-
parathyroidism in a long-term followup after total parathy-
roidectomy with presternal intramuscular autotransplanta-
tion in patients with secondary and tertiary hyperparathy-
roidism.
2. Patients andMethods
2.1. Study Design. This is a prospective study on a cohort of
operated patients treated at a university referral center. All
surgeries were performed by the same surgeon.
This investigation was approved by the UNIFESP/EPM
Ethics Committee (approval no. CEP 1091/05).
2.2. Patients. Two hundred and twelve patients under-
went parathyroidectomy from April 2000 to April 2005 at
Hospital S˜ ao Paulo and Hospital do Rim UNIFESP/EPM,
S˜ ao Paulo, Brazil. Those patients were followed at the
Renal Osteodystrophy Unit in our institution and were
referred to surgical treatment in face of persistent hyper-
calcemia not responsive to medical interventions and/or
persistent hyperphosphatemia despite the continued use
of dietary phosphorus restriction and phosphate-binding
agents, symptoms as intractable pruritus, severe bone pain,
fractures or high risk of fracture, skeletal deformities, extra2 Journal of Osteoporosis
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Figure 1: Parathyroid gland fragments sized 2mm3 selected for presternal autotransplantation.
Table 1: Characteristics of patients and preoperative laboratory
ﬁndings.
SHPT THPT
N (number of patients) 38 28
Sex (female : male) 24:14 14:14
Mean age (years) 39.2 (14–58) 43.4 (24–62)
Years on dialysis 7.8 (1–13) 6.12 (2–20)
Years of renal graft 2.6 (1–7)
iCa 1.35 (1.18–1.40) 1.59 (1.42–1.77)
p 6.6 (4.5–11.8) 2.7 (1.6–6.3)
AP 877 (130–2900) 311 (74–1304)
iPTH 1711 (516–2500) 442 (109–1758)
SHPT: secondary hyperparathyroidism; THPT: tertiary hyperparathy-
roidism, iCa: Serum-ionized calcium, P: phosphorus; AP: alkaline phos-
phatase; iPTH: intact parathyroid hormone. Reference values: iCa: 1.11–
1.40mmol/L; P: 2.3–4.6mg/dL; AP: 35–129U/L; iPTH: 10–65pg/mL.
skeletal calciﬁcations, development of calciphylaxis, and
radiographic evidence of renal osteodystrophy. From the
212 patients who underwent total parathyroidectomy with
presternal autotransplantation, 66 had at least 1 year of
postoperative followup with enough reported data to be
eligible for the study.
These 66 patients were divided into two groups: the ﬁrst
included renal patients in dialysis treatment (N = 38),
deﬁned as secondary hyperparathyroidism (SHPT) group
and the second group included patients with kidney graft
(N = 28), deﬁned as tertiary hyperparathyroidism (THPT)
group. Secondary hyperparathyroidism is characterized as
an acquired disorder seen in end-stage renal disease, in
which the uremic state presents a continuous stimulus
to the parathyroid glands. We included in the SHPT
group patients under dialysis treatment who presented
severe hyperparathyroidism without hypercalcemia. Tertiary
hyperparathyroidism group was composed by renal patients
with kidney transplant with nonsuppressible parathyroid
hyperplasia,withpersistentincreasediPTHlevelsandhyper-
calcemia even after restoration of normal renal function.
Hypercalcemia after kidney transplantation is usually due
to hyperparathyroidism that persists from the preceding
chronic kidney disease period [2].
Serum-ionized calcium (iCa), phosphorus (P), alkaline
phosphatase (AP), and intact parathyroid hormone (PTH)
were measured before parathyroidectomy (Table 1)a n d
yearly after surgery in all patients from both groups.
Deﬁnitive hypoparathyroidism was described when PTH
measurements under 10pg/mL endures 1 year after parathy-
roidectomy, with normal or low-serum calcium levels under
vitamin D and oral calcium replacement.
Hyperparathyroidism recurrence after surgery was de-
ﬁned when high levels of intact PTH were observed through-
out late postoperative followup that failed to respond to
medical/pharmacological management.
2.3. Methods. Total parathyroidectomy with intramuscular
presternal autotransplantation was performed in 66 patients
from April 2000 to April 2005. Those patients were evaluated
inaprospectivemanner1to8yearsaftersurgery.Allofthem
had at least four-gland excision conﬁrmed by frozen section
examination and/or intraoperative PTH measurement (IO-
PTH available in 43 patients) so as to conﬁrm surgical cure.
Removed parathyroid glands were carefully examined
in order to select a parathyroid area (non nodular region)
for implant and cryopreservation. The selected parathyroid
fragment was gently diced into small pieces measuring
approximately 2.0mm3,and 60 to 65 pieces of suitable
parathyroid graft were obtained by this technique (Figure 1).
Around 30 parathyroid fragments were implanted in prester-
nal musculature over a single area of 1.5cm in length.
A horizontal 1.5cm incision was made over the upper
one-third of the sternum above left 2nd intercostal space
(Figure 2). Pectoralis major muscle insertion at sternum
bone [3–5] was identiﬁed followed by fascia and muscle
ﬁbers dissection in an attempt to perform a 1.5cm graft
pocket where parathyroid fragments were implanted. This
grafted area had sternum bone as posterior boundary.
Muscular fascia and the superﬁcial part of the presternal
musculature are sutured with a nonabsorbible ﬁlament.Journal of Osteoporosis 3
Figure 2: Intramuscular presternal grafted area: ﬁnal aspect.
The suture prevented parathyroid graft extrusion and con-
tributed as a marker of the grafted area.
After skin incision had been closed, remaining sterile
parathyroid pieces were frozen at −70◦Ci nas o l u t i o nc o n -
taining 60% of RPMI or DMEM, 30% of fetal bovine serum
and 30% of DMSO (dimetilsulfoxide), thus cryopreserved
for further reimplant, if needed.
Intraoperative PTH (IO-PTH) was performed in an
attempt to conﬁrm total removal of the parathyroid glands,
so as to avoid overlooking remaining or supernumerary
hyperfunctioning glands. IO-PTH was measured by resort-
ing to the Elecsys PTH Immunoassay (Elecsys 1010 System,
Roche, Mannheim, Germany). The time required to carry
out the assay is 9 minutes, and reference values are 10–
70pg/mL. Peripheral venous blood sample (4.0mL) was
obtained immediately after induction of anesthesia and 20
minutes after removal of all parathyroid glands [6, 7].
Phosphorus, total alkaline phosphatase, and creatinine
were measured by means of standard automatic assays
(Hitachi 912, Roche). Serum-ionized calcium was measured
by using an ion-speciﬁc electrode (AVL 9180 Electrolyte
Analyzer, Roswell, GA, USA). Parathyroid hormone was
measured by immunometric assay (Immulite, DPC, Med-
Lab) (Table 1).
3. Results
Overall, 66 patients underwent total parathyroidectomy
with presternal intramuscular autotransplantation and were
e v a l u a t e di nap r o s p e c t i v em a n n e ri na na v e r a g ef o l l o w u p
of 42.9 months (ranging from 12 to 96 months). There
were 38 patients in SHPT group, of whom 24 were women
and 14 were men, with a mean age of 39.2 years (ranging
from 14 to 58). There were 28 patients in THPT group, 14
female and 14 male, aged 43.4 years on average, ranging
from 24 to 62. Patients from SHPT group presented with
an average of 7.8 years under dialysis treatment before
parathyroidectomy, and THPT group comprised patients
who had undergone dialysis treatment for an average of 6.12
years before receiving a kidney graft, with an average of
2.6 years of functional renal graft before parathyroidectomy
(Table 1).
Intraoperative PTH measurements revealed a percentage
decrease of 87% on average in patients considered cured,
ranging from 67.8% to 94.4%. Only one patient was not
cured after four-gland excision, whose intraoperative PTH
decrease was only 62.1%. Moreover, further surgical explo-
ration revealed a 5th parathyroid gland, which was excised
followed by 70.2% intraoperative PTH level decrement.
Postoperative PTH levels increased throughout follow-
up in both groups, from 73.5pg/mL on average in the ﬁrst
year to 133pg/mL on average in the 5th in SHPT group and
from 54.9pg/mL on average in the ﬁrst year to 94.7pg/mL
on average in the 5th in THPT (Table 2).
Deﬁnitive hypoparathyroidism was observed in 4
(6.06%) patients, 3 of whom in SHPT group and 1 in THPT
group.
Graft-dependent recurrence was observed in 6 patients
(Table 3, bold data). All of them occurred in patients
under dialysis treatment years after total parathyroidectomy
with presternal autotransplantation. Diagnosis of graft-
dependent recurrence was conﬁrmed by positive sestamibi
99mTc investigation, followed by presternal graft surgical
removal.
Bone biopsy with mineralized bone histology after
double tetracycline labeling was performed in 11 patients
(16.6%) prior to surgery. The results observed were osteitis
ﬁbrosa in 6 patients (with osteoporosis components in 2 and
aluminum staining in 3), mixed uremic osteodystrophy in 4
(with osteoporosis components in 2, aluminum staining in
1), and adynamic bone in 1 patient.
4. Discussion
Secondary hyperparathyroidism is a common complication
in patients with renal chronic disease. Before currently
available medical and surgical therapies, SHPT used to
result in considerable morbidity and mortality, including
crippling bone disease [2]. It is worth highlighting that
the ideal treatment for patients with renal chronic disease
concerns kidney graft. Nevertheless, not all patients are
eligible for this treatment, once due to clinical counter-
indications, or unfavorable socioeconomic-educational lim-
itations. Unfortunately, we still have diﬃculties in providing
kidney transplantation for all patients with renal chronic
failure in our country, thus exposing them to an undesirable
long-term dialysis treatment.
The longer survival of renal chronic disease patients
increased the incidence of symptomatic hyperparathy-
roidism condition [8]. The incidence of parathyroidectomy
in renal patients is about 5 per 1,000 patients-year during
the ﬁrst 2 to 3 years of dialysis; however, the rates rise
to over 40 per 1,000 patients-year among patients who
underwent maintenance dialysis for 10 years or more [9].
Similarly, the prevalence of parathyroidectomy in end-
stage renal disease ranges from 9.2% after 10–15 years in
dialysis to 20.8% after 16–20 years in dialysis treatment4 Journal of Osteoporosis
Table 2: Intact PTH (pg/mL) measurements in the followup.
1st year 2nd year 3rd year 4th year 5th year >5yrs
SHPT (n = 38) 73.5 82 80 82 133 102.6
THPT (n = 28) 54.9 61.7 70.5 74.3 94.7 98.5
SHPT: secondary hyperparathyroidism group; THPT: tertiary hyperparathyroidism group; reference value for iPTH: 10–65pg/mL.
Table 3: Patients followup with graft-dependent recurrence years after surgery.
Recurrence 1st-year PTH/Cai 2nd-year PTH/Cai 3rd-year PTH/Cai 4th-year PTH/Cai 5th-year PTH/Cai After 5yrs
PTH/Cai
Patient 1 937/0.9
Patient 2 13/1.40 51/1.4 1165/1.29
Patient 3 66/1.16 84/1.27 198/1.3 611/1.3
Patient 4 67/1.16 104/1.29 132/1.08 162/1.28 1155/1.02
Patient 5 22/0.90 168/1.56 569/1.53
Patient 6 925/1.3
Reference values: iCa: 1.11–1.40mmol/L; iPTH: 10–65pg/mL.
[1]. Therefore, parathyroidectomy rates rise along with
time on dialysis treatment [9, 10]. In patients eligible for
surgery, parathyroidectomy is generally considered when
hyperparathyroidism is severe and refractory to medical
management,usuallyafteratherapeutictrialofcalcitrioland
a vitamin D analog, or when medical management to reduce
iPTH levels results in unacceptable rises in levels of serum
calcium and/or phosphorus, or when medical management
is not tolerated because of adverse eﬀects [2]. Our study
reviewed a patient cohort prior to the use of calcimimetics,
which may play an eﬀective role in the clinical management
of renal patients; however, such drug is still not available
in our country for all chronic renal disease patients. Even
in kidney-transplanted patients, parathyroidectomy is an
important therapeutic approach, appearing to be safe for
renal function regardless of the technique employed [11].
The best surgical approach for renal hyperparathy-
roidism remains controversial in the literature. In 1960,
Stanbury et al. were the ﬁrst to perform a successful parathy-
roidectomy with a subtotal technique, where a parathyroid
fragment remained in the neck, supplied by its own blood
vascular source [12]. In an attempt to avoid high postopera-
tive hyperparathyroidism recurrence, in 1967 Ogg proposed
total parathyroidectomy for renal patients with no kidney
transplant perspective [13]. This technique relies on the idea
that microscopic residual parathyroid tissue is present in the
thymus [14], which should be able to sustain an adequate
hormone level and thus prevent the adynamic bone disease
[15]. Nonetheless, deﬁnitive hypoparathyroidism is a harm-
ful condition, mainly in kidney transplant patients in whom
hypoparathyroid states are highly symptomatic and diﬃcult
to control. Moreover, total parathyroidectomy not followed
by immediate parathyroid tissue reimplantation may not be
indicated for patients with renal chronic disease awaiting
kidney transplantation [2]. Once this technique with total
parathyroidectomy without autotransplantation leads to
harmful deﬁnitive hypoparathyroidism condition, Wells et
al., in 1975 and 1977, reported their experience in total
parathyroidectomy with parathyroid autotransplantation in
forearm musculature and parathyroid tissue cryopreserva-
tion for further reimplant if needed [16–18]. This innovative
approach has enabled into a new surgical view: parathyroid
transplantation, cryopreserved parathyroid tissue viability,
and cryopreserved parathyroid transplantation. Therefore,
total parathyroidectomy with forearm autograft,as proposed
by Wells et al. in 1975, has been considered the standard
p r o c e d u r ee v e rs i n c e[ 16]. In this technique, parathyroid
fragments are grafted into forearm brachioradialis or ﬂexor
muscle group, where each parathyroid fragment is placed
in a separate bed. This approach is in agreement with
the idea of feasible recognition and treatment of possible
graft-dependent recurrence. Parathyroid graft would be
easily recognized in this location, and excision might be
performed under local anesthesia. In addition, parathyroid
graftfunctionwouldthenbeevaluatedbasedoncomparative
PTH measurements between grafted and nongrafted arm.
Nevertheless, that technique has presented some restric-
tions. In 1978, Wells described four (13%) normocalcemic
patients with no oral medicine intake, in whom PTH mea-
s u r e m e n t sw e r eu n d e t e c t a b l ei ng r a f t e da r m[ 19]. Regarding
the graft removal experience, in 1979 Wells reported three
(7.5%) patients with graft-dependent hyperparathyroidism,
of whom one presented with persistent hyperparathyroidism
even after parathyroid graft was excised [20]. Seeking to
avoid these undesirable recurrence outcomes, other authors
have studied diﬀerent receptor areas: Jansson and Tisell, in
subcutaneous abdominal adipose tissue [21], Kinnaert et
al., in presternal subcutaneous region [22], Chou et al. and
Monchik et al., in subcutaneous forearm tissue [8, 23], and
Lieu et al., into the sternocleidomastoid muscle [24]. Since
then, forearm musculature has not longer been considered
the sole receptor area.
It has been reported that autotransplantation of parathy-
roid tissue should meet the following requirements: only
recently removed parathyroid tissue should be transplanted,
the implantation site should be easily accessible duringJournal of Osteoporosis 5
neck surgery, and, in case of recurrent hyperparathyroidism
or inﬁltrating growth, part, or all, of the parathyroid
tissue should be easily removed [21]. Many centers have
abandoned cryopreservation because of a lack of success
in reimplantation of cryopreserved tissue, and only use
fresh tissue, if possible. In our study, we have evaluated
patients with renal chronic disease who underwent total
parathyroidectomy with intramuscular presternal autotrans-
plantation. By resorting to this technique, we fulﬁlled the
idealrequirementsbyusingfreshtissuefortransplantationin
accessible graft area during neck surgery. Taking recurrence
risk into account, this surgical approach revealed low levels
of graft-dependent recurrence rates (6 recurrences in 66
patients), presenting feasible graft surgical removal under
local anesthesia. It is worth noting that all recurrences
occurred in patients under dialysis treatment. Therefore,
the most important reason for recurrence concerns not to
surgical approach itself, but long-lasting renal disease, once
no recurrence was observed among kidney-grafted patients
throughout extensive followup.
This study presents some limitations. One is concerned
to unknown levels of vitamin D, once that measurements
were not available in our service. Another limitation is
relatedtopeculiaritiesinthestudygroup:thatmarkedilland
long-lastingrenalpatientsareaspecialgroupwhoseoutcome
would not be expected in current patients with renal chronic
disease. Unfortunately, that severe illness observed in our
patients is a rare condition. Third, we do not have, until
present date, other studies with the same surgical approach
so as to properly compare surgical results.
The ideal serum concentrations of intact PTH to be
achieved after surgery remain controversial for patients with
renal chronic disease, once neither adynamic bone disease
nor high recurrence rate is intended [25]. Acknowledging
that intact PTH levels are yet to be deﬁned, we have reached
intact PTH levels around 100pg/mL in both groups (SHP
and THP) and a low occurrence of deﬁnitive hypoparathy-
roidism (6,06%), thus showing interesting results with this
surgical approach.
5. Conclusion
In conclusion, presternal intramuscular autotransplantation
of parathyroid tissue is a feasible and safe surgical option
in SHPT and THPT treatment, at least as eﬀective as other
surgical approaches.
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